Sir Robert McAlpine has been awarded a £22m contract for Manchester Science Partnership’s Citylabs 2.0 development.
Citylabs 2.0 is the first phase of a larger £60m planned expansion. It will provide a site for innovation in genomics, medicine development, translational science, and molecular diagnostics. Citylabs 2.0 has already been wholly pre-let to global molecular diagnostics company QIAGEN and will become its European hub for diagnostics development. QIAGEN is expanding and relocating from Manchester Science Park.
Citylabs 2.0’s 92,000 sq ft development is slated for completion by the end of 2020. It is promised to generate over 1,500 jobs and give a £150m boost to the city’s economy. It will be designed by Sheppard Robson, and is located directly opposite Royal Manchester Children’s Hospital.
“This is an important milestone in our journey to create a world-leading precision medicine campus in Manchester,” said Tom Renn, managing director of Manchester Science Partnerships. “It will strengthen the region’s standing as a global centre of excellence in life sciences and diagnostics, bringing real health benefits to millions of people, and supporting the creation of thousands of high-quality jobs.
“We look forward to supporting our long-standing customer QIAGEN as they continue with their ongoing growth and expand into Citylabs 2.0 once it completes at the end of 2020.”
Simon Trevor, central, Wales and west regional managing director for Sir Robert McAlpine, added: “We look forward to working with Manchester Science Partnerships on the extension of the Citylabs campus. Building on 150 years of technical excellence and innovation, we take pride in delivering complex projects that make a positive impact on communities and leave a lasting legacy, such as this state-of-the-art medical facility.”
Citylabs 2.0 is part-funded by the European Regional Development Fund. The project is being developed by Bruntwood as part of a ten- year strategic property partnership with Manchester University NHS Foundation Trust.